Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 574 matching trials from the live ClinicalTrials.gov search.
Conditions
Opioid Use Disorder
Interventions
Recovery Connect
Device
Lead sponsor
Bright Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
9
States / cities
Anchorage, Alaska • Wasilla, Alaska • Billings, Montana + 6 more
Completed Not applicable Interventional Results available

Protocolized Care for Early Septic Shock

NCT00510835
Conditions
Sepsis, Severe Sepsis, Septic Shock
Interventions
Early Goal Directed Therapy (EGDT), Protocolized Standard Care (PSC), Usual Care (UC)
Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
1,351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 23 more
Enrolling by invitation Not applicable Interventional

Heart to Heart: BP Control Partners

NCT05809713
Conditions
Hypertension
Interventions
Technology-enabled Team Care, Enhanced Usual Care
Other
Lead sponsor
East Carolina University
Other
Eligibility
19 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Greenville, North Carolina • Wilmington, North Carolina
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulce Digital, Dulce Digital-Me (Automated Delivery), Dulce Digital-Me (Medical Assistant)
Behavioral
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Chula Vista, California • La Jolla, California
Conditions
Chronic Pain
Interventions
Cognitive Behavioral Therapy (CBT), Exercise Counseling and tele-EnhanceFitness, Care Coordination, Standard Clinical Practice Regimen
Behavioral · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Obstructive Sleep Apnea
Interventions
SleepWell24 Application
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset, Inflammation
Interventions
Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 69 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Conditions
Migraine
Interventions
Preventative Medication (PM), Enhanced Usual Care, PMR (progressive muscle relaxation therapy)
Drug · Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

NCT03323437
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders
Interventions
Risperidone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Tetralogy of Fallot, Double Outlet Right Ventricle
Interventions
N-thymidine, Urine Collection, Echocardiogram, Cardiac MRI (CMR), Propranolol Hydrochloride, Placebo, Physical Exam, Specimen Collection
Other · Procedure · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Days to 60 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Conditions
Narcolepsy Type 1, Hypersomnia, Sleep Disorder
Interventions
Dreem 3S recording
Device
Lead sponsor
Beacon Biosignals
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Fontana, California • Redwood City, California • Rochester, New York + 1 more
Completed Not applicable Interventional Results available

Project SMART Automated Pillbox Study

NCT04418076
Conditions
HIV/AIDS, Cocaine Use
Interventions
Group A_No feedback, Group B_Automated feedback, Group C_Automated feedback + Clinician feedback, Group D_Automated feedback + Social Network feedback
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Localized Esophageal Carcinoma, Localized Lung Carcinoma, Pathologic Stage 0 Esophageal Adenocarcinoma AJCC v8, Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage I Esophageal Adenocarcinoma AJCC v8, Pathologic Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma AJCC v8, Stage 0 Lung Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Cardiac Event Monitor, Chemoradiotherapy, Radiation Therapy
Procedure · Device · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Not applicable Interventional Accepts healthy volunteers

Texting for Relapse Prevention

NCT02819349
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Texting for Relapse Prevention (T4RP)
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Obsessive - Compulsive Disorder
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS), Supportive Therapy (ST), Exposure and Response Prevention (ERP) Therapy
Device · Behavioral
Lead sponsor
Adam Frank
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Advanced Cancers
Interventions
Nuclear Medicine Cardiac Scan, PET/CT Cardiac Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Spinal Cord Injuries
Interventions
Robotic Gait Training, Usual Care Gait Training
Device · Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
16 Years to 85 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use

NCT00535769
Conditions
Skin Cancer
Interventions
Electronic + no text message, Electronic monitor + text messages
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Liquid Biopsy for Early Non-small Lung Cancer Detection

NCT05462795
Conditions
Non Small-cell Lung Cancer
Interventions
Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
Diagnostic Test
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Completed Phase 4 Interventional Accepts healthy volunteers

Modafinil Effects on EEG Biomarkers of Reward and Motivation

NCT03616717
Conditions
Healthy Adults
Interventions
Modafinil, placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Antidepressant Effects of Nitrous Oxide

NCT05357040
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
HIV
Interventions
Incentive intervention model
Behavioral
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
16 Years to 24 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Type1diabetes
Interventions
Insulin pump
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
6 Years to 18 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer
Interventions
[F-18]RGD-K5
Drug
Lead sponsor
Siemens Molecular Imaging
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Irvine, California • Los Angeles, California • Newark, New Jersey + 2 more